Back

Meta-analysis of randomized trials: DEB versus DES in patients with de novo coronary artery disease

1 September 2025 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Choosing the optimal devices in percutaneous coronary intervention Devices ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Himanshu Rai

Mater Private Network, Dublin 7 (Ireland)

7 More presentations in this session

Presentation thumbnail
Outcomes in functionally guided DCB versus stent PCI: a propensity-matched analysis
Professor A. Leone (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Long-term outcomes of drug coated balloons versus drug eluting stents in patients with small vessel coronary artery disease
Assistant Professor M. Arab (Zagazig, EG)
Abstract Slides Video
Presentation thumbnail
Sex-specific outcomes following percutaneous coronary interventions with drug-coated balloons
Miss L. Stutz (Luzern, CH)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes of stent-less percutaneous coronary intervention with intravascular lithotripsy and drug-coated balloon for severely calcified de novo coronary lesions.
Doctor T. Misawa (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Comparison of two different paclitaxel-coated balloons in small native coronary vessel disease
Doctor J. Lee (Incheon, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Choosing the optimal devices in percutaneous coronary intervention

The Event

Event poster

ESC Congress 2025

1 September 2025 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Drug-coated ballons vs drug-eluting stent in de novo coronary lesions, a propensity-score matched cohort study
thumbnail
Congress Presentation
Usage patterns and outcomes of drug coated ballons at a tertiary care center - a cohort analysis in 462 patients
thumbnail
Congress Presentation
Drug-coated balloon versus drug-eluting stent revascularization in the treatment of de novo acute myocardial infarction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources